Tobinai, K., Klein, C., Oya, N., & Fingerle-Rowson, G. (2016). A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies. Adv Ther.
Style de citation ChicagoTobinai, Kensei, Christian Klein, Naoko Oya, et Günter Fingerle-Rowson. "A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients With B-Cell Malignancies." Adv Ther 2016.
Style de citation MLATobinai, Kensei, Christian Klein, Naoko Oya, et Günter Fingerle-Rowson. "A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients With B-Cell Malignancies." Adv Ther 2016.
Attention : ces citations peuvent ne pas être correctes à 100%.